MANNKIND CORP (MNKD) earnings date
Feb 25, 2027, after close estimated
Estimated from the company's SEC filing cadence. The company has not confirmed it. Companies usually announce two to four weeks ahead.
- Fiscal period
- Q4 FY2026
- Confidence
- 45% chance of landing within a day
- Source
- Filing history on EDGAR
- Last checked
- 2026-11-19
Read by software from public filings and company announcements. Can be wrong. Verify with the company or the SEC. Not investment advice.
How this company behaves
| Announces its report date | Not enough announcements on file yet to say |
| Reports after the quarter ends | 36 days, typically, give or take 10 (last 8 releases) |
Last 8 releases
| Period | Released | Timing | Days after period end | Filing |
|---|---|---|---|---|
| Q3 FY2026 | Thu, Nov 5, 2026 | after close | 36 | 8-K |
| Q2 FY2026 | Wed, Aug 5, 2026 | after close | 36 | 8-K |
| Q1 FY2026 | Wed, May 6, 2026 | after close | 36 | 8-K |
| Q4 FY2025 | Thu, Feb 26, 2026 | before open | 57 | 8-K |
| Q3 FY2025 | Wed, Nov 5, 2025 | before open | 36 | 8-K |
| Q2 FY2025 | Wed, Aug 6, 2025 | before open | 37 | 8-K |
| Q1 FY2025 | Thu, May 8, 2025 | before open | 38 | 8-K |
| Q4 FY2024 | Wed, Feb 26, 2025 | after close | 57 | 8-K |
What they guided beta
| Q3 FY2026 | "Anticipate earning $15 million in milestone payments in 2027 Inhaled GLP-1 Program" exhibit |
| Q3 FY2026 | "The Furoscix on-body infusor has a lower gross margin percentage than Afrezza which resulted in a decrease in gross margin in the current period. Research and development expenses were $14.4 million for the three months ended September 30, 2026, compared to $14.1 million for the same period in 2025, an increase of 2%. The increase was primarily attributable to the development of Furoscix ReadyFlow, higher personnel costs following the acquisition of scPharma, and increased clinical development costs for MNKD-201." exhibit |
| Q3 FY2026 | "These increases were partially offset by lower clinical development expenses resulting from the discontinuation of the ICoN-1 clinical study for MNKD-101 and the completion of the Afrezza pediatric study. Selling, general and administrative expenses were $61.4 million for the three months ended September 30, 2026, compared to $29.1 million for the same period in 2025, an increase of 111%. The increase was primarily attributable to costs associated with the promotion and support of Furoscix, which was acquired from scPharma in October 2025, expansion of our field-based teams, and launch a" exhibit |
| Q3 FY2026 | "The Furoscix on-body infusor has a lower gross margin percentage than Afrezza which resulted in a decrease in gross margin in the current period. Research and development expenses were $49.6 million for the nine months ended September 30, 2026, compared to $38.8 million for the same period in 2025, an increase of 28%. The increase was primarily attributable to the development of Furoscix ReadyFlow, higher personnel costs following the acquisition of scPharma, and increased clinical development costs for MNKD-201." exhibit |
| Q3 FY2026 | "These increases were partially offset by lower clinical development expenses resulting from the discontinuation of the ICoN-1 clinical study for MNKD-101 and the completion of the Afrezza pediatric study. Selling, general and administrative expenses were $173.8 million for the nine months ended September 30, 2026, compared to $85.7 million for the same period in 2025, an increase of 103%. The increase was primarily attributable to costs associated with the promotion and support of Furoscix, expansion of our field-based teams, and launch activities related to Furoscix ReadyFlow and the ped" exhibit |
| Q2 FY2026 | "Received FDA approval of Furoscix ReadyFlow™ on July 23, 2026, the first and only autoinjector delivering IV-equivalent diuretic therapy for the treatment of edema in adults with heart failure (HF) or chronic kidney disease (CKD); expected to be commercially available in late August Afrezza" exhibit |
| Q2 FY2026 | "Gross margin percentage decreased in the current period due to the inclusion of Furoscix, which has a lower gross margin percentage than Afrezza. Research and development expenses were $18.0 million for the three months ended June 30, 2026, compared to $13.7 million for the same period in 2025, an increase of 32%. The increase was primarily attributable to the development of the Furoscix ReadyFlow Formulation as well as higher personnel costs following the acquisition of scPharma and increased development costs for MNKD-201, which has begun enrolling subjects." exhibit |
| Q2 FY2026 | "The increase was partially offset by lower clinical development expenses resulting from the discontinuation of the ICoN-1 clinical study for MNKD-101 and the completion of the Afrezza pediatric study (INHALE-1). Selling, general and administrative expenses were $58.3 million for the three months ended June 30, 2026, compared to $31.6 million for the same period in 2025, an increase of 84%. The increase was primarily related to costs associated with the promotion and support of Furoscix, as well as expanding our field-based teams and activities to support the launches associated with the " exhibit |
| Q2 FY2026 | "Gross margin percentage decreased in the current period due to the inclusion of Furoscix, which has a lower gross margin percentage than Afrezza. Research and development expenses were $35.2 million for the six months ended June 30, 2026, compared to $24.7 million for the same period in 2025, an increase of 43%. The increase was primarily attributable to the development of the Furoscix ReadyFlow Formulation as well as higher personnel costs following the acquisition of scPharma and increased development costs for MNKD-201, which has begun enrolling subjects." exhibit |
| Q2 FY2026 | "The increase was partially offset by lower clinical development expenses resulting from the discontinuation of the ICoN-1 clinical study for MNKD-101 and the completion of the Afrezza pediatric study (INHALE-1). Selling, general and administrative expenses were $112.4 million for the six months ended June 30, 2026, compared to $56.6 million for the same period in 2025, an increase of 98%. The increase was primarily related to costs associated with the promotion and support of Furoscix, as well as expanding our field-based teams and activities to support the launches associated with the re" exhibit |
Get this as JSON
curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/next/MNKD
# how far back the record goes for this company
curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/coverage/MNKD
Put this date on your page
A badge that stays current. It links back to this page and needs no key. Embed it unmodified, with its link to this page intact: the badge is too small to carry the notice below, so the page it links to does.
Read by software from public filings and company announcements. Can be wrong. Verify with the company or the SEC. Not investment advice.
HTML
<a href="https://veritasdata.dev/company/MNKD/"><img src="https://veritasdata.dev/embed/MNKD.svg" alt="MNKD earnings date" width="240" height="56"></a>
Markdown
[](https://veritasdata.dev/company/MNKD/)
Script
<script async src="https://veritasdata.dev/embed/MNKD.js"></script>
Get a free key: 100 calls, every company
Sign in with GitHub or Google. The key works on every endpoint and in the MCP server.
curl -H "X-API-Key: vt_live_..." "https://api.veritasdata.dev/v1/next/MNKD"
Dates come only from SEC EDGAR and company announcements. Nothing here is investment advice.